Antioxidant supplements do not improve male fertility, NIH study suggests
Antioxidant supplements do not improve semen quality among men with infertility, according to a new study supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health. The study also found that antioxidant supplements likely do not improve pregnancy and live birth rates. The study appears in Fertility and Sterility.
Antioxidant supplements are commercially available to help treat male infertility, but research on its effects on semen quality and rates of pregnancy and live birth are limited. The new study reports on results from the Males, Antioxidants, and Infertility Trial (MOXI), a double-blind, randomized, placebo-controlled clinical study conducted at nine sites across the United States. The study enrolled 171 couples where the male partner had at least one abnormal reading on an analysis evaluating sperm concentration, mobility, shape and DNA quality; the female partners had normal fertility test results. Men received a placebo or an antioxidant supplement containing vitamins C, E and D, selenium, l-carnitine, zinc, folic acid and lycopene for at least three months and up to six months. MOXI was supported by NICHD’s Reproductive Medicine Network.
The study team found no statistically significant differences in sperm concentration, mobility, shape and DNA quality between the placebo and antioxidant groups after three months. Furthermore, live birth rates did not seem to differ at six months between the antioxidant (15%) and placebo (24%) groups. However, the authors note that per the study design, recruitment was stopped before it reached the desired number of participants because no benefits were seen in the antioxidant group. Therefore, the authors only had enough participants to evaluate statistical differences in semen quality but not in pregnancy and live birth rates.
According to the authors, MOXI is the largest randomized, placebo-controlled trial to examine the effects of antioxidants, without additional assisted reproductive technology, on male infertility.
Study author Esther Eisenberg, M.D., M.P.H., of NICHD’s Fertility and Infertility Branch is available for interviews.
Steiner AZ et al. The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility DOI: 10.1016/j.fertnstert.2019.11.008 (2020)
About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): NICHD leads research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all. For more information, visit https://www.nichd.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
ver historia personal en: www.cerasale.com.ar [dado de baja por la Cancillería Argentina por temas políticos, propio de la censura que rige en nuestro medio]//
weblog.maimonides.edu/farmacia/archives/UM_Informe_Autoevaluacion_FyB.pdf - //
weblog.maimonides.edu/farmacia/archives/0216_Admin_FarmEcon.pdf - //
www.proz.com/kudoz/english_to_spanish/art_literary/523942-key_factors.html - 65k - // www.llave.connmed.com.ar/portalnoticias_vernoticia.php?codigonoticia=17715 // www.frusculleda.com.ar/homepage/espanol/activities_teaching.htm // http://www.on24.com.ar/nota.aspx?idNot=36331 ||